Insights into the clinical value of cyclin-dependent kinase 5 in glioma: A retrospective study

27Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Previous studies suggested that expression of cyclin-dependent kinase 5 (CDK5) may promote the migration and invasion of human glioma cells. In this study, we aimed to evaluate the clinical value of CDK5 in different grades of glioma in relation to Ki-67 labeling index (LI). Methods: We firstly assessed by immunohistochemistry the expression of CDK5 in 152 glioma tissues and 16 normal brain tissues and further explored the relationship between CDK5 expression and other clinical features. Results: The positive ratio of CDK5 in gliomas (57.2 %) was higher than that in normal brain tissues (12.5 %, P = 0.001). Difference of CDK5 expression among four World Health Organization (WHO) grades was statistically significant (P = 0.001). The significant differences of CDK5 expression were also observed between WHO I glioma (34.8 %) and WHO III glioma (62.5 %), as well as WHO IV glioma (82.8 %; P = 0.026, P < 0.001, respectively). Furthermore, Spearman's rank correlation confirmed that CDK5 was positively correlated with the pathological grade of glioma (r = 0.831, P < 0.001). The CDK5 expression was also positively correlated with Ki-67 LI (r = 0.347, P < 0.001). Conclusions: The current result suggests that CDK5 may play an essential role in the tumorigenesis and aggressiveness of gliomas.

Figures

  • Fig. 1 Expression of CDK5 in different grade glioma tissues. a WHO I glioma; b WHO II glioma; c WHO III glioma; d WHO IV GBM
  • Fig. 2 The implication of CDK5 expression and Ki-67 LI in different tissues. a CDK5-positive expression was higher in glioma tissues than in normal brain tissues (P = 0.002). The positive rate of CDK5 expression in WHO III and WHO IV was also significantly higher than in WHO I (P = 0.021, P = 0.020, respectively); b CDK5 expression was significantly higher in high-grade gliomas than low-grade gliomas (P < 0.001); c the significant differences of Ki-67 LI among the different groups; d higher Ki-67 LI was detected in high-grade gliomas than in low-grade gliomas (P< 0.001). *P< 0.05;**P< 0.01;***P< 0.001
  • Table 1 Association of CDK5 expression and Ki-67 LI with clinicopathological features
  • Fig. 3 The comparison of Ki-67 LI between CDK5-positive and CDK5-negative group. The CDK5-positive group revealed higher Ki-67 compared to the negative one (P < 0.001)
  • Fig. 4 The ROC curves for the predicative value of Ki-67. a AUC of Ki-67 LI for diagnosing gliomas was 0.903 (95 % CI 0.840, 0.967; P < 0.001); b Ki-67 LI as ≥7.5 could predict high-grade WHO glioma (AUC = 0.982, 95 % CI 0.967, 0.998; P = 0.008)

References Powered by Scopus

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Yushan, R., Wenjie, C., Suning, H., Yiwu, D., Tengfei, Z., Madushi, W. M., … Gang, C. (2015). Insights into the clinical value of cyclin-dependent kinase 5 in glioma: A retrospective study. World Journal of Surgical Oncology, 13(1). https://doi.org/10.1186/s12957-015-0629-z

Readers over time

‘15‘16‘18‘19‘20‘21‘22‘2402468

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 4

44%

Professor / Associate Prof. 3

33%

Researcher 2

22%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 5

42%

Agricultural and Biological Sciences 4

33%

Medicine and Dentistry 2

17%

Pharmacology, Toxicology and Pharmaceut... 1

8%

Save time finding and organizing research with Mendeley

Sign up for free
0